OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+7.41%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$124M
AUM Growth
+$124M
(+4.7%)
Cap. Flow
+$454K
Cap. Flow
% of AUM
0.37%
Top 10 Holdings %
Top 10 Hldgs %
38.32%
Holding
72
New
6
Increased
25
Reduced
8
Closed
17
Top Buys
| 1 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$3.23M |
| 2 |
AstraZeneca
AZN
|
$3.19M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$925K |
| 4 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
$876K |
| 5 |
ARRY
Array Biopharma Inc
ARRY
|
$865K |
Top Sells
| 1 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
$4.15M |
| 2 |
PCYC
PHARMACYCLICS INC
PCYC
|
$3.48M |
| 3 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
$1.73M |
| 4 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$912K |
| 5 |
Tenax Therapeutics
TENX
|
$812K |
Sector Composition
| 1 | Healthcare | 83.4% |
| 2 | Financials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $5.35M | 4.23% | 28,124 +2,445 | +10% | +$465K |
|
|
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.05M | 4% | 104,339 -6,711 | -6% | -$325K |
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $4.91M | 3.89% | 35,899 +3,354 | +10% | +$459K |
|
|
4
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $4.84M | 3.83% | 53,568 +35,784 | +201% | +$3.23M |
|
5
Illumina
ILMN
$15.8B
| $4.68M | 3.71% | 21,451 +842 | +4% | +$184K |
|
|
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.61M | 3.65% | 52,400 -3,588 | -6% | -$315K |
|
7
Nektar Therapeutics
NKTR
$568M
| $4.6M | 3.65% | 367,963 +32,313 | +10% | +$404K |
|
8
Alkermes
ALKS
$4.78B
| $4.57M | 3.62% | 71,022 +8,476 | +14% | +$545K |
|
9
Biogen
BIIB
$19.4B
| $4.55M | 3.6% | 11,254 +1,923 | +21% | +$777K |
|
10
Regeneron Pharmaceuticals
REGN
$61.5B
| $4.47M | 3.54% | 8,759 +9 | +0.1% | +$4.59K |
|
|
CELG
11
DELISTED
Celgene Corp
CELG
| $4.44M | 3.52% | 38,375 +5,086 | +15% | +$589K |
|
12
Incyte
INCY
$16.5B
| $4.36M | 3.46% | 41,873 -1,809 | -4% | -$189K |
|
13
Vertex Pharmaceuticals
VRTX
$100B
| $4.36M | 3.45% | 35,276 +2,471 | +8% | +$305K |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.19M | 3.32% | 34,979 -2,409 | -6% | -$289K |
|
|
MDVN
15
DELISTED
MEDIVATION, INC.
MDVN
| $3.92M | 3.11% | 34,344 +3,597 | +12% | +$411K |
|
|
CPHD
16
DELISTED
Cepheid Inc
CPHD
| $3.89M | 3.08% | 63,635 +8,942 | +16% | +$547K |
|
|
ALXN
17
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $3.88M | 3.07% | 21,474 -557 | -3% | -$101K |
|
18
Ionis Pharmaceuticals
IONS
$6.79B
| $3.81M | 3.02% | 66,208 +5,296 | +9% | +$305K |
|
19
Mettler-Toledo International
MTD
$26.8B
| $3.76M | 2.97% | 11,000 +1,564 | +17% | +$534K |
|
|
QGENF
20
DELISTED
QIAGEN NV
QGENF
| $3.47M | 2.75% | 140,000 +17,276 | +14% | +$428K |
|
21
Bio-Techne
TECH
$8.5B
| $3.35M | 2.65% | 34,000 +3,083 | +10% | +$304K |
|
22
Pacira BioSciences
PCRX
$1.2B
| $3.32M | 2.63% | 47,000 +12,051 | +34% | +$852K |
|
|
23
AstraZeneca
AZN
$248B
| $3.19M | 2.52% | +50,000 | New | +$3.19M |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $2.31M | 1.83% | 320,000 +120,000 | +60% | +$865K |
|
25
Hologic
HOLX
$14.9B
| $1.83M | 1.45% | 48,000 -2,000 | -4% | -$76.1K |
|